[Sentinel lymph nodes in oral and pharyngeal cancer]. / Sentinel-Lymphknoten bei Mundhöhlen- und Rachen-Tumoren.

The excision of sentinel lymph nodes has a growing relevance in the diagnosis of oral and oropharyngeal cancer in cases of clinical N0 necks. The validity of sentinel node biopsy as minimally invasive staging tool of the neck in T1-2 tumours can be considered as proven due to most recent international multicentre studies. The present paper describes the technique and follows the newest European guide lines.

Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma.

Involvement of the cervical lymph nodes is the most important prognostic factor for patients with oral/oropharyngeal squamous cell carcinoma (OSCC), and the decision of whether to electively treat patients with clinically negative necks remains a controversial topic. Sentinel node biopsy (SNB) provides a minimally invasive method for determining the disease status of the cervical node basin, without the need for a formal neck dissection. This technique potentially improves the accuracy of histologic nodal staging and avoids overtreating three-quarters of this patient population, minimizing associated morbidity. The technique has been validated for patients with OSCC, and larger-scale studies are in progress to determine its exact role in the management of this patient population. This document is designed to outline the current best practice guidelines for the provision of SNB in patients with early-stage OSCC, and to provide a framework for the currently evolving recommendations for its use. Preparation of this guideline was carried out by a multidisciplinary surgical/nuclear medicine/pathology expert panel under the joint auspices of the European Association of Nuclear Medicine (EANM) Oncology Committee and the Sentinel European Node Trial (SENT) Committee.

18F-FDG PET for detecting metastases and synchronous primary malignancies in patients with oral and oropharyngeal cancer.

AIM: Assessment of the efficiency of 18F-FDG-PET (PET) for the detection of distant metastases and synchronous primary malignancies in patients with oral and oropharyngeal squamous cell cancer (OOSCC). PATIENTS, METHODS: Retrospective evaluation of PET studies of 422 patients with histologically confirmed OOSCC. 99 patients (23.5%) demonstrated a suspect distant finding of whom 84 could be interdisciplinary evaluated and consecutively confirmed or refuted by other diagnostic modalities or biopsy. RESULTS: In 74 of 80 evaluable cases, PET showed the primary tumour (92.5%). 26/84 suspect distant lesions (31%) showed by means of PET were confirmed to be malignancies (mean SUV 3.96; range 1.4-9.37). Main sites were the lung, the upper aerodigestive tract, and the gastrointestinal system. In the other 58 cases (69%), where the suspect lesions were confirmed as benign, mean SUV was 2.65 (range 0.7-6.5) (difference statistically significant). The SUV above which every suspect finding was proven to be of malignant condition was 6.5 (specificity 100%, sensitivity 38%, accuracy 81%). CONCLUSION: PET may have an important role in initial staging and the detection of distant metastases and synchronous primary malignancies. Setting a SUV threshold for determining malignancies can support interpretation. In borderline cases, however, interdisciplinary evaluation by means of other diagnostic modalities remains crucial.

[Intraorbital tumours of the peripheral nervous system]. / Intraorbitale Tumoren des peripheren Nervensystems.

In neoplastic processes in the orbital area, a not significant part of these new entities is caused by tumours of the peripheral nervous system. Due to a clinically similar behaviour and radiological features also being similar, these tumours sometimes cause differential diagnostic difficulties. Our experience with these tumours shows that they do not have a uniform symptom complex. Exophthalmus and displacement of the globe are the most visible symptoms besides pain, motility disturbances, reduced visus and double images. Clinical imaging allows the exact localisation of the tumour and makes it easier to choose the best surgical method. However, imaging does not allow the exact assessment of the entity or enable a decision to be made about the possible malignancy of the tumour. Therefore, a representative biopsy and a histopathological examination are essential. Then, a complete tumour resection should be performed using the most careful incision possible to avoid postoperative complications.

[Clinical and histopathological results after local chemoembolization of oral and oropharyngeal carcinoma--comparison with intraarterial chemoperfusion]. / Klinische und histopathologische Ergebnisse nach lokaler Chemoembolisation oraler und oropharyngealer Karzinome--Vergleich mit intraarterieller Chemoperfusion.

PURPOSE: Retrospective analysis of clinical and histopathological results after neoadjuvant intraarterial chemoembolization (iaCE) as compared to intraarterial chemoperfusion (iaCP) in patients with oral and oropharyngeal squamous cell cancer (SCC). MATERIALS AND METHODS: 289 patients (mean age 60 years, 68 % male) with SCC of the oral cavity or the oropharynx (WHO stage I-IV) received (1) neoadjuvant iaCE (n = 103) with a crystalline suspension of cisplatin (150 mg/m(2), solution ratio 5 mg cisplatin ad 1 ml NaCl 0.9 %, total volume 40 - 60 ml) or (2) iaCP (n = 186) using high-dose cisplatin infusions (150 mg/m(2), 1 mg cisplatin ad 1 ml NaCl 0.9 %, 400 - 500 ml). The decision for iaCE or iaCP was made individually for each patient based on tumor localization and expected vascular supply. Four weeks after local chemotherapy, the treatment response was evaluated according (1) to WHO criteria and (2) to histopathological TNM-grading after tumor resection. RESULTS: The overall treatment response was 72.5 % after iaCE and 47 % after iaCP (p < 0.001). A stable disease was found in 24 % and 48 %, respectively, and tumor progression was found in 3 % for both modalities. Histopathological examination of resected tumors revealed complete remission in 20 % after iaCE and 13 % after iaCP. The percentage of complete remissions was highest in local T1 and T2 tumors after iaCE (42.9 versus 22.4 % after iaCP, p = 0.031). Local side effects were significantly more frequent after iaCE than after iaCP (p < 0.001), especially in obese patients with extended carcinoma of the oral floor or the tongue base. CONCLUSION: Compared to iaCP, clinical and histopathological remission rates are significantly higher after iaCE, especially in early stages of local tumor growth. However, in view of the higher risk of regional complications, indication for iaCE should be considered cautiously and its application should be limited to small tumors of the oral floor and the oral tongue.

FDG uptake after intraarterial chemotherapy in head and neck cancer.

AIM: The intraarterial chemotherapy (i.a.CHT) using high dose cisplatin combined with systemic neutralization in patients with head and neck cancer (HNSCC) is used to reduce the tumor volume preoperatively. Aim of the study is the evaluation of the influence of i.a.CHT on the metabolism of fluor-18-deoxyglucose (FDG) in the primary and lymph nodes (LN). The value of FDG positron emission tomography (PET) preoperative and as follow-up method after i.a.CHT is examined. PATIENTS, METHODS: Altogether 16 patients with HNSCC underwent two preoperative FDG PET examinations: the baseline examination one week before and the follow-up three weeks after i.a.CHT. The SUVmax values of the primary and the LN and LN metastases were evaluated and compared with each other and the histopathology. RESULTS: The SUVmax value of the primary decreased after i.a.CHT significantly from a median (25 (th) percentile/75 (th) percentile) of 6.4 (4.1/7.8) to 3.6 (2.4/6.7) (p = 0.01). In 11 out of 16 patients cervical LN metastases were detected. The cervical LN metastases showed a decrease of the SUVmax value from 3.6 (2.3/4.8) in the pretreatment examination to 2.3 (1.7/3.6) after i.a.CHT (p = 0.008). Only in one patient with LN metastases the SUVmax of the nodes increased. The histopathologically measured size of the LN metastases ranged from 2 to 30 mm. Non malignant LN did not reveal a significant SUVmax decrease after i.a.CHT (p = 0.13). CONCLUSIONS: As expected, primaries of HNSCC showed a significant reduction of SUV after i.a.CHT. Compared to the primary the SUVmax decrease in LN metastases was less, but also significant. Since cytotoxic levels of cisplatin do not occur systemic, postinflammatory reactions of the LN or a lymphatic drainage of the chemotherapeutic drug into the LN could be an explanation. PET for staging of HNSCC must thus be performed prior to i.a.CHT.

Intra-arterial high-dose chemotherapy with cisplatin as part of a palliative treatment concept in oral cancer.

BACKGROUND AND PURPOSE: Patients with cancer of the oral cavity often present with advanced tumor stages, distant metastasis, or severe comorbidities, which render radical surgery unfeasible. The purpose of this study was to investigate the response rate, technical feasibility, and safety of intra-arterial (IA) chemotherapy as palliative treatment in this situation. METHODS: From November 1997 to December 2003, 64 patients with histologically proven oral squamous cell carcinoma, classified as inoperable, received IA high-dose chemotherapy with cisplatin as a palliative treatment at our institution. To minimize toxic side effects, sodium thiosulfate was given intravenously. Twenty-eight percent of the patients were female; average age was 61.5 years. Clinical staging of primary tumors was TNM (tumor, nodules, metastases) stage IV in 89%, stage III in 6.3% and stage II in 4.7%. After local chemotherapy, additional radiation of the tumor area or radiochemotherapy was performed in 33 patients. RESULTS: There were no major catheter-related complications or severe side effects of IA chemotherapy. After the first cycle, 10% percent of the patients had complete remission (CR), 35% had partial response (PR), and 43.3% presented with stable disease. Mean follow-up interval was 11 +/- 12.9 months. Forty-five patients died after a mean period of 7.6 +/- 7.0 months (median, 5.1 months). The overall 1- and 2-year survival rates were 29.5% and 18%, respectively. There was a trend toward longer survival in patients who received subsequent radiation or radiochemotherapy after IA chemotherapy. CONCLUSION: IA chemotherapy in patients with inoperable carcinoma of the oral cavity as palliative treatment was technically feasible and safe. The overall response rate after IA chemotherapy was 45% (CR 10%; PR 35%). Side effects could be minimized by neutralizing the cytotoxic agent by sodium thiosulfate.

A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy.

AIMS: Recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) develops in around 72,000 people in Europe every year. Treatment options are limited, mainly consisting of platinum-based palliative chemotherapy, with median overall survival times of only 6-8 months. No standard second-line treatment after progression on platinum-based chemotherapy is available. Few data have reported the efficacy of these treatments and the outcome of the patients. In an effort to generate such data, this retrospective study analysed clinical records from 151 patients with SCCHN refractory to platinum-based chemotherapy treated between 1990 and 2000 at seven different centres around Europe. MATERIALS AND METHODS: Most patients (45%) received only best supportive care (BSC), and had a median survival of 56 days. A total of 28.5% of the patients received second-line chemotherapies: 16.6% radiotherapy and 9.9% chemoradiotherapy. RESULTS: No objective response was observed with the various second-line chemotherapies. The overall median survival was 103 days (95% confidence interval [CI]: 77-126 days) for the whole cohort. The overall objective response rate (ORR) to second-line treatment in this population was calculated to be 2.6%. CONCLUSION: These results highlight the need for additional treatment options for this disease. Similar, if not superior, response rates have already been observed in initial clinical studies of novel, targeted anti-cancer agents.

[Cephalometric studies on X-ray pictures to evaluate postoperative cranial growth of children with craniosynostoses]. / Kephalometrische Untersuchungen an Röntgenbildern zum postoperativen Schädelwachstum von Kindern mit Kraniosynostosen.

OBJECTIVE: A preoperative CT scan seems indispensible for the evaluation of the bones and soft tissue in children with craniosynostoses. Regular postoperative follow-up is limited because of general anaesthesia and radiation exposure. Therefore, cranial growth of these children has hardly been examined so far. A method is needed to replace CT for this indication and to allow differentiated growth analysis besides clinical inspection. METHODS: 15 children (7 trigonocephalies, 4 plagiocephalies, 4 syndromal craniosynostoses) were operated on using a standardized bilateral fronto-orbital advancement. Using conventional pre- and postoperative skull roentgenograms, a craniometric analysis according to the modified method of Schmid et al. [13] was carried out. RESULTS: A supernormal opening of the frontal angle (the forehead area) and an increase of length of the frontal base were found. Skull height and skull width were positively influenced; the growth of the dorsal skull base remained retarded in length postoperatively. There was metrically identifiable reorganization of areas distant from operation area. Results were validated by comparison with normal subjects and patient populations known from the published literature. CONCLUSION: The presented method is easy, safe and exposure-reduced, and is able to assess the growth of different skull areas by means of distance and angle measurements. It should be used regularly in routine postoperative control of craniosynostoses. CT examinations should be limited to special questions of the soft tissue.

Limitations of dual time point FDG-PET imaging in the evaluation of focal abdominal lesions.

AIM: For the evaluation of the diagnostic potential of dual time point FDG positron emission tomography (PET) in patients with suspicious focal abdominal uptake, dual time point PET imaging was compared with clinical findings. PATIENTS, METHODS: In a prospective study, 56 patients exhibiting a solitary suspicious, intense abdominal FDG uptake, underwent dual time point PET imaging for staging or restaging of different malignant tumors, maximal standardized uptake value (SUVmax) measurements included. The first acquisition was started 64.8 +/- 19.5, the second 211.3 +/- 52.5 min after FDG injection. The final diagnosis based on CT or MRT imaging and a follow-up period of 12.6 +/- 2.8 months. Additionally, colonoscopy was done in 6 patients. In another 6 patients histopathology was obtained from CT guided biopsy. RESULTS: Malignant focal abdominal lesions with a SUVmax <2.5 (n = 4) showed an uptake increase of > or =30%. In the remaining malignant cases with an uptake of > or =2.5 (n = 11), uptake increased in 64% and decreased in 36%. Malignant lesions showing FDG uptake decrease (n = 4) had an initial SUVmax value > or =2.5 and remained with a SUVmax > or =2.5 in the second imaging. In benign lesions with an initial SUVmax > or =2.5 (n = 31), the uptake increased in 17 patients (55%) and decreased in 14 patients (45%). All lesions which changed configuration (33%) were confirmed as benign (n = 5). CONCLUSION: Using dual time point PET abdominal lesions show a very hetergenous uptake pattern regardless of their dignity. Malignancy can only be reliably excluded in lesions which change their configuration and in lesions with an initial SUVmax value <2.5 combined with an SUV decrease in the delayed imaging. Particularly abdominal lesions which show an initial SUVmax > or =2.5 combined with a SUV increase in the delayed imaging are suspicious for malignancy and need further clarification.

Long-term complete remission of oral cancer after anti-neoplastic chemotherapy as single treatment modality: role of local chemotherapy.

The impact of intra-arterial local chemotherapy on squamous cell carcinomas of the oral cavity is doubtful when considering long-term survival, especially in cases of nodal involvement. But even in patients with strictly local disease it is not possible to determine the effect of intra-arterial chemotherapy because it is mainly used as a neoadjuvant treatment modality. In the present paper, long-term courses of two patients are described who refused any further treatment after one cycle of intra-arterial chemotherapy with cisplatin followed by systemic chemotherapy with 5-fluorouracil and one cycle of intra-arterial chemotherapy with high-dose cisplatin, respectively. The aim of the paper is to demonstrate the potential of local chemotherapy in responders. The impact of this treatment modality in incurable patients is discussed, too. This may offer a point in favor of use of intra-arterial chemotherapy in combination treatment regimens.

Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results.

Adjuvant chemotherapy has not yet been proven to have a survival benefit for patients with head and neck cancer. Studies dealing with this topic have had several faults like mingling tumor localizations and treatment modalities. To re-examine the role of postoperative chemotherapy in oral cavity cancer, a single-center study was conducted with the attempt to have higher homogeneity. 122 patients with primary squamous cell carcinoma of the lip, the oral cavity and the oropharynx have been treated with 100 mg/m2 cisplatin bolus infusion and 120-h continuous infusion of 1000 mg/m2 5-fluorouracil following radical surgery; 99 patients completed all 3 cycles. The disease-free and overall survival are reported and compared to a control group of 161 patients with cancer of the lip, the oral cavity and oropharynx treated only with surgery, and a treatment-dependent prognostic index. After a median follow-up of 79 months (range 5-18 years), the current 5-year overall survival of the chemotherapy group was 67% and the 5-year disease-free survival was 57% while the respective data for the control group are 46% and 40%. This difference is statistically significant. The comparison with the prognostic index confirmed this result. The chemotherapy group suffered from fewer local and more neck relapses and had a much longer relapse latency (29 months versus 8 months). The toxicity of the chemotherapy regimen was tolerable. In a homogeneous population with resectable oral cavity and oropharyngeal cancer, postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil resulted in a high overall survival rate which was significantly better than in a comparable population treated only with surgery and better than the survival expectation calculated with the help of a prognostic index. A prospective randomized study of postoperative chemotherapy versus control, exclusively in patients with oral cancer, is warranted.

Influence of the prosthetic restoration modality on bone loss around dental implants placed in vascularized iliac bone grafts for mandibular reconstruction.

OBJECTIVES: Is bone loss associated with implants placed in vascularized iliac crest bone grafts for mandibular reconstruction dependent on the prosthetic restoration modalities used? STUDY DESIGN: Eleven vascularized iliac crest bone grafts for mandibular reconstruction were examined after ablative tumor surgery. Forty implants loaded for at least 1 year were observed for up to 6 years. Horizontal and peri-implant bone loss was assessed for 2 groups: 6 patients with implant-supported bridges and 5 patients with implant-retained overdentures. RESULTS: Horizontal bone loss reached a steady state around 2 mm after an observation time of 2 years. Bony pockets had a depth of less than 1 mm. The described pattern was nearly independent of the prosthetic restoration modality used. The implant survival rate was 97.6%. CONCLUSIONS: Vascularized iliac crest bone grafts are safe implant-bearing areas. Implant-retained overdentures can be used with as good a longterm efficacy as the more complicated implant-supported bridges.

Comparison of two types of arterialized venous forearm flaps for oral reconstruction and proposal of a reliable procedure.

The mechanism of survival of venous flaps is not yet completely understood. To determine the conditions for reliable success, in 1996 and 1997 we used arterialized venous forearm flaps for oral reconstruction in patients with neoplastic disease. Building on earlier experience with flow-through flaps, we compared two different designs obeying the following specifications: five so-called arterialized flow-through flaps, elevated from the ulnar flexor side of the forearm, with a single vein for orthograde inflow and outflow, diameter not larger than 2 mm (type 1); and five arterialized flaps with two parallel veins on the proximal side of the flap, also with a diameter of 1-2 mm, to avoid by-passing of flap tissue by 'catching' the blood in the venous/capillary system (type 2). There were nine male and one female patients with a mean age of 55.7 years. We covered defects of the anterior or anterolateral floor of the mouth to avoid folding of the flaps. Microsurgical anastomosis was done to the facial artery, the cranial thyroid artery and the external jugular vein or the facial vein. Average size of the flaps was 23 +/- 7.28 cm2 (type 1) and 25 +/- 5 cm2 (type 2). Four flaps of type 1 showed total or subtotal success and only one was lost because of a haematoma. In comparison with this we saw three losses in type 2 and only one partial and one total success, respectively. Analysis showed regularly occurring problems: there was failure of venous drainage in the lost type 2 flaps one day after microsurgery. In the flow-through flaps and the surviving type 2 flaps which had visible communicating branches between the two veins, the partial by-passing of the arterial input avoided this problem. There was no donor site morbidity after covering with a split-thickness skin graft. It could be shown that survival of arterialized venous forearm flaps is based on a combination of an arteriovenous shunt and capillary blood flow. In conclusion, we define six rules for a reliable venous forearm flap.

Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI.

BACKGROUND: The choice of treatment in patients with oral malignancies depends on accurate pretreatment staging and particularly the detection of lymph node involvement. Therefore staging of the neck should be as accurate as possible. PATIENTS: One hundred and six patients with histologically proven squamous cell carcinoma of the oral cavity. STUDY DESIGN: In a prospective study, PET using fluoro-desoxy-glucose (18F-FDG), ultrasound, CT and MRI of head and neck were compared with the postoperative histologic tissue evaluation. Two thousand one hundred and ninety-six neck lymph nodes of 106 patients were investigated. In all patients the tumour was resected and a lymph node dissection was performed. RESULTS: The diagnostic procedures showed the following results when compared with the histological findings: PET: sensitivity 70%, specificity 82%, accuracy 75%; Ultrasound: 84%, 68%, 76%; CT: 66%, 74%, 70%; MRI: 64%, 69% 66%. Thus PET showed the highest specificity while ultrasound had the highest sensitivity compared with the other staging procedures. A nonsignificant correlation was found between the size of a lymph node metastasis and the ability to detect it. In 10 patients, second primary tumours or distant metastases were detected by PET only. CONCLUSION: Due to the high number of small lymph node metastases from oral cavity carcinoma, the non-invasive neck staging methods are limited to a maximum accuracy of 76%. Elective neck treatment should be mandatory for all patients with squamous cell carcinoma of the oral cavity.

Intraarterial chemotherapy as neoadjuvant treatment of oral cancer.

Neoadjuvant chemotherapy in patients with primary squamous cell carcinomas of the oral cavity should lead to high remission rates whilst having low morbidity. Efficacy can also be enhanced by treating small tumour stages. As part of a multi-modality therapy of all stages of primary oral cavity carcinoma, 103 patients were treated with neoadjuvant intraarterial (i.a.) chemotherapy. After regimen A with 100 mg/m2 i.a. cisplatin followed by 5 day continuous intravenous infusion of 5-fluorouracil (1 g/m2 per day) in 36 patients, an i.a. high pressure chemo-perfusion with a dose of 150 mg/m2 cisplatin was used with simultaneous intravenous infusion of 9 g/m2 sodium thiosulfate (regimen B, 67 patients). Subsequent treatment comprised radical surgery and simultaneous radiochemotherapy with docetaxel. Partial and complete remissions were found in 80.6% (regimen A) and 67.2% (regimen B) of cases, tumour growth was inhibited in 11.1% and 31.3%. Very low toxicity could be shown especially in regimen B. 66.7% and 74.6% of patients could be operated on radically. Survival rate was 61.1% (regimen A, 22.7 months of mean observation time) and 79.1% (regimen B, 8.4 months). Patients with high-grade remissions seemed to have a survival advantage. Neoadjuvant i.a. chemotherapy with cisplatin, especially in its high dose variant, is a practical therapeutic tool for the treatment of all stages of primary oral cavity carcinoma.

Influence of chemotherapy on endosteal implant survival and success in oral cancer patients.

Little is known about the effect of chemotherapy on the osseointegration and survival of endosteal dental implants. In a retrospective study, two groups of patients were compared: one group consisting of 30 oral cancer patients received postsurgical adjuvant chemotherapy with either cis- or carboplatin and 5-fluorouracil in three cycles and were treated subsequently with 106 dental implants placed in the mandible; the other group consisting of 17 patents suffering from oral cancer was prescribed with 54 dental implants placed in the mandible after oncological surgery. No patient was treated with radiotherapy. Twenty patients in the first group were successfully provided with a prosthetic superstructure (mean time of function: 35.8 months) compared to 16 patients in the second group (mean time of function: 36.2 months). The observation time was 10 years. A life-table analysis based on defined success parameters demonstrated no significant difference between implant survival in either group. It was concluded that chemotherapy with cis- or carboplatin and 5-fluorouracil was not detrimental to the survival and success of dental implants in the mandible.

Relevance of positive margins in case of adjuvant therapy of oral cancer.

Positive or clean surgical margins are of great prognostic interest in the surgical treatment of oral and oropharyngeal cancer with poor survival of patients burdened with positive margins. The impact of postoperative treatment modalities on the survival of these patients is debated. The relevance of positive margins was investigated in three patient populations (a group treated by surgery only, a group with postoperative polychemotherapy, and a group with a multi-modality treatment comprising postoperative radiation with concurrent chemotherapy) which were compared retrospectively. Patients treated with adjuvant regimens following resection in healthy margins had a survival advantage as compared to the surgery only group possibly due to less local relapses and longer relapse latencies. Overall disease-free survival was better in the groups with adjuvant therapy irrespective of free or positive margins. Survival rates following positive surgical margins were worse in all three groups as compared to the respective subgroups with healthy margins. A second resection in patients with positive margins, executed in the group with postoperative radiation with concurrent chemotherapy, did not result in survival improvement. Therefore, radical resection at initial surgery in healthy and clear margins remains indispensable in multi-modality treatment strategies involving surgery. The combination of healthy margins and adjuvant treatment seems to be most favorable for patient survival.

Minimization of zygomatic complex fracture treatment.

The aims of this non-randomized prospective study were to establish and justify minimized therapy for zygomatic complex fractures. Fifty-two consecutive patients were examined and classified with conventional routine radiographs. Preoperative symptoms were recorded. Treatment of zygomatic fractures was by percutaneous hook reduction and miniplate fixation along the frontozygomatic suture. Exploration of the orbital floor was carried out only in cases of primary diplopia or comminuted fractures. Postoperatively, patients were followed for 12 months. Clinical and radiologic assessment of reduction was symmetric and stable in all cases. Preoperative symptoms disappeared completely except for sensitivity disturbance in five patients. Patients with no post-trauma diplopia did not develop eye motility disturbances or enophthalmos. The treatment of a zygomatic fracture is possible by the described technique. Exploration of the orbital floor is indicated only in cases of preoperative diplopia. Therefore, a patient with a zygomatic fracture and diplopia should be classified as having a orbitozygomatic fracture. In cases of comminuted fractures, exploration of the orbital floor remains mandatory.

Assessment of prosthetic restorations on bone-lock implants in patients after oral tumor resection.

The feasibility of implant treatment in patients after oral ablative tumor surgery has not yet been investigated with consideration of the requisite high periodontal standards. A report on this topic has to deal not only with implant survival but also with implant health, bone response, soft tissue health, failure pattern, time of failure, and ease of restoration. For the assessment of an implant system, an overview must be accomplished that takes into account the different restorations used and their interaction with the implant system that was used. This study presents the Bone-Lock implant system (Howmedica Leibinger GmbH, Freiburg, Germany) in a retrospective investigation after 5 years of follow-up with special emphasis on the prosthetic restorations used following resection of oral malignancies. From early in 1990 through June 1996, we inserted 210 dental endosteal Bone-Lock implants (58 patients) after oral tumor resectioning. Included in the study were 45 patients with 162 implants and prosthetic restorations that had been loaded for 1 year (dentures retained by telescopic or bar-clip or ball attachments, implant-supported prostheses, tooth-to-implant connected bridges). Regular follow-up consisted of evaluation of the Plaque Index (Silness and Löe) and of the Sulcus Bleeding Index (Löe), measurements of pocket probing depth, implant mobility (by means of the Periotest method), bone resorption (according to X-ray findings), and a questionnaire that registered patient satisfaction. The results were evaluated for each restoration and were compared with baseline standards. The overall 5-year survival rate was 83.2%. For implants that had been in place for over 365 days, the survival rate was 93%. The investigation showed that after resection of oral malignancies, patients could be treated with dental implants and superstructures with long-term efficacy similar to that found in healthy subjects considering internationally accepted standards. Implant treatment in tumor patients appeared to offer the most positive periodontic results when use of bar-clip or telescope-retained overdentures was involved. The patient satisfaction level with the described prosthodontic treatment was satisfactory.